Distinct molecular mechanisms responsible for bortezomib-induced death of therapy-resistant versus -sensitive B-NHL cells.
about
Bortezomib for the treatment of mantle cell lymphoma: an updateProteasome inhibition represses unfolded protein response and Nox4, sensitizing vascular cells to endoplasmic reticulum stress-induced death.Pevonedistat, a NEDD8-activating enzyme inhibitor, is active in mantle cell lymphoma and enhances rituximab activity in vivoUpdate on treatment of follicular non-Hodgkin's lymphoma: focus on potential of bortezomibBortezomib for the treatment of non-Hodgkin's lymphomaThe novel proteasome inhibitor carfilzomib induces cell cycle arrest, apoptosis and potentiates the anti-tumour activity of chemotherapy in rituximab-resistant lymphomaMitotic catastrophe and cell cycle arrest are alternative cell death pathways executed by bortezomib in rituximab resistant B-cell lymphoma cellsMLN2238, a proteasome inhibitor, induces caspase-dependent cell death, cell cycle arrest, and potentiates the cytotoxic activity of chemotherapy agents in rituximab-chemotherapy-sensitive or rituximab-chemotherapy-resistant B-cell lymphoma preclinicNon-canonical NF-κB Plays a Pivotal Role in Non-Hodgkin's Lymphoma.
P2860
Q26738940-458D6B4D-5CC9-4390-BCAB-7E31B6D9CDEBQ33812818-2B703219-824B-40E2-99DC-9E60EB12A2A6Q34505392-EDB7D5D9-3E24-44D4-8DEC-CD274652FA4EQ35905929-961E9267-C476-4F93-9215-D9068CF5B895Q36868056-42E7EAFE-EE7D-4786-AAED-90F56A6A4D65Q37140809-FC6E552F-F695-4BFA-BB6C-75E8CBCBEC84Q37706483-51E5D020-41DE-4E2C-8686-7423CF452390Q39101546-4072AFA0-6241-44ED-8A80-9FCF243D1B31Q51676680-CA642FCD-B045-4242-84E6-027E4EBF7CC6
P2860
Distinct molecular mechanisms responsible for bortezomib-induced death of therapy-resistant versus -sensitive B-NHL cells.
description
2010 nî lūn-bûn
@nan
2010 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Distinct molecular mechanisms ...... versus -sensitive B-NHL cells.
@ast
Distinct molecular mechanisms ...... versus -sensitive B-NHL cells.
@en
Distinct molecular mechanisms ...... versus -sensitive B-NHL cells.
@nl
type
label
Distinct molecular mechanisms ...... versus -sensitive B-NHL cells.
@ast
Distinct molecular mechanisms ...... versus -sensitive B-NHL cells.
@en
Distinct molecular mechanisms ...... versus -sensitive B-NHL cells.
@nl
prefLabel
Distinct molecular mechanisms ...... versus -sensitive B-NHL cells.
@ast
Distinct molecular mechanisms ...... versus -sensitive B-NHL cells.
@en
Distinct molecular mechanisms ...... versus -sensitive B-NHL cells.
@nl
P2093
P2860
P1433
P1476
Distinct molecular mechanisms ...... versus -sensitive B-NHL cells.
@en
P2093
Alan Belicha-Villanueva
Cory Mavis
Francisco J Hernandez-Ilizaliturri
James L Clements
Jennifer Blickwedehl
John Gibbs
Myron S Czuczman
Naveen Bangia
Scott H Olejniczak
Wasif Riaz
P2860
P304
P356
10.1182/BLOOD-2009-12-259754
P407
P577
2010-10-07T00:00:00Z